Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00532233 · ClinicalTrials.gov registry record · Phase 2

SD, IL-13 Production Rate in IPF

A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
52
Enrollment target
6
Study locations

NCT00532233 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 52 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00532233, a Phase 2 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
52 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • DRUG QAX576

Study Locations (6)

Colorado

  • Novartis Investigative Site - Denver

Georgia

  • Novartis Investigative Site - Atlanta

Louisiana

  • Novartis Investigative Site - New Orleans

Minnesota

  • Novartis Investigative Site - Rochester

North Carolina

  • Novartis Investigative Site - Durham

Pennsylvania

  • Novartis Investigative Site - Pittsburgh

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2007-09
Est. Completion 2009-06
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00532233

The ClinicalTrials.gov registry entry for NCT00532233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which QAX576 is the first listed.

NCT00532233 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Georgia, Louisiana.

Frequently Asked Questions

What is clinical trial NCT00532233 about?

NCT00532233 is a clinical study titled "SD, IL-13 Production Rate in IPF". The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).

What is the current status of trial NCT00532233?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2007-09. Estimated completion is 2009-06.

What conditions does trial NCT00532233 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT00532233?

The interventions under investigation include: QAX576 (DRUG).

Who is sponsoring clinical trial NCT00532233?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00532233 being conducted?

This trial has 6 study locations across Colorado, Georgia, Louisiana, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.